Passage Bio Financials

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

Passage Bio Stock Summary

Passage Bio competes with Ikena Oncology, Eliem Therapeutics, HCW Biologics, RenovoRx, and Tempest Therapeutics. Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania. Passage Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 133 people.

Passage Bio Key Financial Ratios

Passage Bio Key Balance Sheet Accounts

Passage Bio Key Income Statement Accounts

Passage Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Passage Bio's current stock value. Our valuation model uses many indicators to compare Passage Bio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Passage Bio competition to find correlations between indicators driving Passage Bio's intrinsic value. More Info.Passage Bio is regarded third in return on equity category among its peers. It is regarded fifth in return on asset category among its peers . At this time, Passage Bio's Return On Equity is most likely to slightly decrease in the upcoming years. Comparative valuation analysis is a catch-all technique that is used if you cannot value Passage Bio by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Passage Bio Systematic Risk

Today, most investors in Passage Bio Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Passage Bio's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Passage Bio growth as a starting point in their analysis.

Along with financial statement analysis, the daily predictive indicators of Passage Bio help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Passage Bio. We use our internally-developed statistical techniques to arrive at the intrinsic value of Passage Bio based on widely used predictive technical indicators. In general, we focus on analyzing Passage Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Passage Bio's daily price indicators and compare them against related drivers.

When running Passage Bio's price analysis, check to measure Passage Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Passage Bio is operating at the current time. Most of Passage Bio's value examination focuses on studying past and present price action to predict the probability of Passage Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Passage Bio's price. Additionally, you may evaluate how the addition of Passage Bio to your portfolios can decrease your overall portfolio volatility.